Profile data is unavailable for this security.
About the company
Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Generics segment includes a retail and institutional portfolio of over 270 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
- Revenue in USD (TTM)2.60bn
- Net income in USD-174.62m
- Incorporated2023
- Employees7.70k
- LocationAmneal Pharmaceuticals Inc400 Crossing Boulevard, 3rd FloorBRIDGEWATER 08807United StatesUSA
- Websitehttps://amneal.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immunocore Holdings PLC - ADR | 281.45m | -53.44m | 1.66bn | 497.00 | -- | -- | -- | 5.90 | -1.07 | -1.07 | 5.55 | -- | 0.3556 | 0.5679 | 5.56 | 566,303.60 | -6.75 | -27.55 | -8.35 | -36.82 | 99.41 | -- | -18.99 | -97.12 | 5.15 | -- | 0.5495 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
| Supernus Pharmaceuticals Inc | 630.16m | 5.24m | 1.75bn | 652.00 | 360.24 | 1.83 | 19.43 | 2.78 | 0.0883 | 0.0883 | 11.39 | 17.39 | 0.4831 | 0.9256 | 4.36 | 966,507.70 | 0.4016 | 4.95 | 0.5117 | 6.41 | 88.34 | 88.61 | 0.8314 | 12.84 | 1.69 | -- | 0.00 | -- | -8.95 | 8.24 | -97.83 | -58.81 | -8.17 | -- |
| Ligand Pharmaceuticals Inc | 133.48m | 42.14m | 1.88bn | 58.00 | 46.20 | 2.40 | 24.30 | 14.07 | 2.22 | 2.22 | 7.33 | 42.82 | 0.1643 | 0.4789 | 4.08 | 2,301,345.00 | 5.19 | 12.32 | 5.35 | 12.99 | 91.82 | 81.65 | 31.57 | 80.32 | 15.81 | -- | 0.00002 | -- | -33.09 | -12.18 | 1,131.21 | -17.86 | 42.63 | -- |
| Endo Inc | -100.00bn | -100.00bn | 2.02bn | 3.00k | -- | 1.10 | -- | -- | -- | -- | -- | 23.99 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.52 | -- | 0.5697 | -- | -13.25 | -- | 15.87 | -- | -- | -- |
| Harmony Biosciences Holdings Inc | 656.11m | 114.99m | 2.23bn | 246.00 | 20.12 | 4.15 | 16.02 | 3.40 | 1.95 | 1.95 | 11.19 | 9.48 | 0.8107 | 25.74 | 8.93 | 2,667,110.00 | 14.21 | 7.46 | 16.68 | 9.08 | 79.41 | 80.58 | 17.53 | 10.46 | 3.09 | 52.20 | 0.2571 | 0.00 | 32.93 | -- | -28.99 | -- | -25.31 | -- |
| Vericel Corp | 214.52m | 789.00k | 2.28bn | 314.00 | 2,462.72 | 9.37 | 384.53 | 10.64 | 0.0189 | 0.0189 | 4.46 | 4.97 | 0.624 | 4.41 | 4.97 | 683,184.70 | 0.2295 | -3.07 | 0.2595 | -3.50 | 70.42 | 67.87 | 0.3678 | -4.49 | 4.16 | -- | 0.0008 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
| Amphastar Pharmaceuticals Inc | 712.89m | 166.52m | 2.39bn | 1.76k | 15.67 | 3.38 | 10.90 | 3.36 | 3.14 | 3.14 | 13.45 | 14.57 | 0.4968 | 2.85 | 6.04 | 404,821.70 | 11.71 | 9.42 | 13.54 | 11.56 | 54.68 | 47.83 | 23.56 | 15.23 | 2.63 | 7.42 | 0.4515 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
| Catalyst Pharmaceuticals Inc | 434.48m | 68.15m | 2.47bn | 167.00 | 38.97 | 4.05 | 23.56 | 5.68 | 0.5335 | 0.5335 | 3.71 | 5.14 | 0.7554 | 4.03 | 8.69 | 2,601,647.00 | 11.85 | 25.42 | 13.56 | 29.81 | 86.67 | 85.63 | 15.69 | 30.87 | 4.94 | -- | 0.00 | 0.00 | 85.90 | 280.39 | -14.05 | -- | 20.21 | -- |
| Amneal Pharmaceuticals Inc | 2.60bn | -174.62m | 2.69bn | 7.70k | -- | -- | 29.26 | 1.04 | -0.6224 | -0.6224 | 10.09 | -0.1857 | 0.7206 | 3.00 | 3.60 | 337,401.60 | -3.69 | -4.80 | -4.93 | -5.93 | 35.04 | 34.76 | -5.13 | -9.00 | 0.8165 | 1.24 | 1.00 | -- | 8.20 | 7.56 | 35.38 | -- | -6.55 | -- |
| Twist Bioscience Corp | 295.21m | -220.31m | 2.72bn | 919.00 | -- | 5.53 | -- | 9.22 | -3.81 | -3.81 | 5.12 | 8.39 | 0.4076 | 5.42 | 8.56 | 321,229.60 | -30.42 | -30.50 | -33.85 | -33.84 | 40.53 | 36.02 | -74.63 | -113.33 | 4.52 | -- | 0.00 | -- | 20.41 | 57.33 | 6.08 | -- | 49.76 | -- |
| Prestige Consumer Healthcare Inc | 1.11bn | 205.13m | 3.62bn | 570.00 | 17.87 | 2.15 | 15.31 | 3.25 | 4.09 | 4.09 | 22.18 | 33.92 | 0.3346 | 3.09 | 6.75 | 1,952,965.00 | 6.17 | 3.69 | 6.42 | 3.84 | 55.32 | 56.79 | 18.43 | 12.19 | 1.90 | 5.26 | 0.3939 | 0.00 | -0.21 | 2.89 | 354.34 | -- | -1.84 | -- |
| Perrigo Company PLC | 4.43bn | -113.90m | 3.70bn | 9.14k | -- | 0.8141 | 16.35 | 0.8358 | -0.833 | -0.9106 | 32.37 | 33.32 | 0.4146 | 2.48 | 5.78 | 484,496.70 | -1.07 | -0.1148 | -1.21 | -0.1315 | 35.93 | 35.28 | -2.57 | -0.2985 | 1.24 | 1.15 | 0.4717 | -- | 4.58 | -0.3238 | 96.64 | -- | -5.95 | 7.52 |
Data as of Sep 20 2024. Currency figures normalised to Amneal Pharmaceuticals Inc's reporting currency: US Dollar USD
26.66%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Credit Suisse Securities (USA) LLC (Broker)as of 30 Jun 2024 | 21.27m | 6.87% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 13.62m | 4.40% |
| Rubric Capital Management LPas of 30 Jun 2024 | 10.72m | 3.46% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 10.04m | 3.25% |
| Citadel Advisors LLCas of 30 Jun 2024 | 9.99m | 3.23% |
| Dimensional Fund Advisors LPas of 30 Jun 2024 | 3.84m | 1.24% |
| Neuberger Berman Investment Advisers LLCas of 30 Jun 2024 | 3.57m | 1.15% |
| Geode Capital Management LLCas of 30 Jun 2024 | 3.41m | 1.10% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 3.39m | 1.09% |
| Nantahala Capital Management LLCas of 30 Jun 2024 | 2.67m | 0.86% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
